US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

0.7797

+0.093713.66%

Post-market: 0.7461-0.0336-4.31%18:41 EDT

Volume:410.15K

Turnover:321.61K

Market Cap:18.65M

PE:-0.88

High:0.8300

Open:0.7100

Low:0.6900

Close:0.6860

52wk High:8.49

52wk Low:0.6042

Shares:23.93M

Float Shares:8.60M

Volume Ratio:1.61

T/O Rate:4.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8859

EPS(LYR):-1.0574

ROE:-553.75%

ROA:-213.40%

PB:18.86

PE(LYR):-0.74

Loading ...

Overview Company News Filings

There is a reason why your super is locked up until your 60s

Morning Star AU

H.C. Wainwright Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Actuate Reports Preclinical Synergy of Elraglusib with RAS Inhibitors in Pancreatic Cancer Models

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with Ras Inhibitors Zoldonrasib and Daraxonrasib

THOMSON REUTERS

Push for major rental change for millions of AussiesThe move would reduce affordability and security problems for renters across the country.3 min read

Actuate Therapeutics Price Target Maintained with a $15.00/Share by HC Wainwright & Co.

Analyst Reiterates Buy on Actuate with Unchanged $15 Price Target Ahead of Key Elraglusib Trials

Actuate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Actuate Therapeutics Q2 FY26 Net Loss Narrows to $4.87 Million; Operating Loss Improves to $4.91 Million

Actuate Therapeutics Inc Expected to Post a Loss of 19 Cents a Share - Earnings Preview

Actuate Therapeutics Initiated at Buy by Rodman & Renshaw

Actuate Therapeutics’ Elraglusib Selected for Evaluation in Beacon2 Trial for High-Risk Pediatric Neuroblastoma

THOMSON REUTERS

Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Actuate Therapeutics posts ASCO presentation on elraglusib plus chemotherapy in metastatic pancreatic cancer

Actuate says Phase 2 data show elraglusib plus chemo lifts survival in first-line metastatic pancreatic cancer

Actuate Therapeutics Announces Asco Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":0.7797,"timestamp":1790798400000,"preClose":0.686,"halted":0,"volume":410149,"hourTrading":{"tag":"盘后","latestPrice":0.7461,"preClose":0.7797,"latestTime":"18:41 EDT","volume":10814,"amount":8241.7754716,"timestamp":1790808071340,"change":-0.0336,"changeRate":-0.043093,"amplitude":0.043093},"delay":0,"changeRate":0.13658892128279868,"floatShares":8604000,"shares":23925852,"eps":-0.885897,"marketStatus":"Post-Mkt","change":0.0937,"latestTime":"09-30 19:10:33 EDT","open":0.71,"high":0.83,"low":0.69,"amount":321609.83185974,"amplitude":0.204082,"askPrice":0.8575,"askSize":100,"bidPrice":0.6632,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.885897,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":4,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":0.686,"preHourTrading":{"tag":"盘前","latestPrice":0.7499,"preClose":0.686,"latestTime":"07:13 EDT","volume":35,"amount":24.323499899999998,"timestamp":1790766812022,"change":0.0639,"changeRate":0.093149,"amplitude":0.09344},"postHourTrading":{"tag":"盘后","latestPrice":0.7461,"preClose":0.7797,"latestTime":"18:41 EDT","volume":10814,"amount":8241.7754716,"timestamp":1790808071340,"change":-0.0336,"changeRate":-0.043093,"amplitude":0.043093},"volumeRatio":1.614957},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":8604000,"roa":"-213.40%","roe":"-553.75%","lyrEps":-1.05737,"volumeRatio":1.614957,"shares":23925852,"dividePrice":0,"high":0.83,"amplitude":0.204082,"preClose":0.686,"low":0.69,"week52Low":0.6042,"pbRate":"18.86","week52High":8.49,"institutionHeld":0,"latestPrice":0.7797,"eps":-0.885897,"divideRate":0,"volume":410149,"delay":0,"ttmEps":-0.885897,"open":0.71,"prevYearClose":6.12,"prevWeekClose":0.68,"prevMonthClose":1.52,"prevQuarterClose":1.53,"fiveDayClose":0.7316,"twentyDayClose":1.54,"sixtyDayClose":1.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"ACTU","fiscalQuarterEnding":"2026/06","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2026-05-14","symbol":"ACTU","fiscalQuarterEnding":"2026/03","expectedEps":-0.23,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2026-03-26","symbol":"ACTU","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2025-11-13","symbol":"ACTU","fiscalQuarterEnding":"2025/09","expectedEps":-0.27,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-08-14","symbol":"ACTU","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1756180800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2026-09-29","current":-0.774356,"percent":0.994424,"low":-9.225925,"twenty":-6.429857,"median":-5.465779,"eighty":-2.465855,"high":-0.727923,"avg":-4.841978,"sd":1.903759,"marketCap":17679255},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-03","current":-5.109147,"twenty":-6.389172,"median":-5.691014,"eighty":-5.046525,"marketCap":129293559},{"date":"2025-07-11","current":-4.791279,"twenty":-6.365148,"median":-5.677284,"eighty":-5.035608,"marketCap":121249498},{"date":"2025-07-18","current":-4.853302,"twenty":-6.320988,"median":-5.645656,"eighty":-4.991444,"marketCap":122819071},{"date":"2025-07-25","current":-5.419262,"twenty":-6.287654,"median":-5.638088,"eighty":-4.976956,"marketCap":137141423},{"date":"2025-08-01","current":-5.620836,"twenty":-6.265937,"median":-5.628589,"eighty":-4.986182,"marketCap":142242535},{"date":"2025-08-08","current":-6.527901,"twenty":-6.287654,"median":-5.632466,"eighty":-4.991444,"marketCap":165196967},{"date":"2025-08-15","current":-6.908485,"twenty":-6.414227,"median":-5.639808,"eighty":-4.995735,"marketCap":170525437},{"date":"2025-08-22","current":-6.442036,"twenty":-6.458702,"median":-5.650353,"eighty":-5.00125,"marketCap":159011858},{"date":"2025-08-29","current":-6.908485,"twenty":-6.483225,"median":-5.670419,"eighty":-5.019908,"marketCap":170525437},{"date":"2025-09-05","current":-7.328709,"twenty":-6.512404,"median":-5.690843,"eighty":-5.033989,"marketCap":180898030},{"date":"2025-09-12","current":-5.859066,"twenty":-6.574176,"median":-5.69465,"eighty":-5.040292,"marketCap":144622132},{"date":"2025-09-19","current":-6.375067,"twenty":-6.549229,"median":-5.726634,"eighty":-5.04517,"marketCap":157358843},{"date":"2025-09-26","current":-6.175411,"twenty":-6.549229,"median":-5.729418,"eighty":-5.051947,"marketCap":152430635},{"date":"2025-10-03","current":-6.212557,"twenty":-6.533707,"median":-5.754096,"eighty":-5.069427,"marketCap":153347511},{"date":"2025-10-10","current":-7.512643,"twenty":-6.537578,"median":-5.770478,"eighty":-5.097386,"marketCap":185438171},{"date":"2025-10-17","current":-7.24334,"twenty":-6.589924,"median":-5.79172,"eighty":-5.109147,"marketCap":178790820},{"date":"2025-10-24","current":-6.732591,"twenty":-6.670885,"median":-5.814177,"eighty":-5.112248,"marketCap":166183775},{"date":"2025-10-31","current":-6.110407,"twenty":-6.6744,"median":-5.859066,"eighty":-5.12,"marketCap":150826102},{"date":"2025-11-07","current":-5.785385,"twenty":-6.670885,"median":-5.869501,"eighty":-5.13638,"marketCap":142803437},{"date":"2025-11-14","current":-5.536933,"twenty":-6.66337,"median":-5.85039,"eighty":-5.154603,"marketCap":136670768},{"date":"2025-11-21","current":-5.868654,"twenty":-6.637844,"median":-5.836285,"eighty":-5.160645,"marketCap":141551867},{"date":"2025-11-28","current":-7.352682,"twenty":-6.647528,"median":-5.86386,"eighty":-5.168486,"marketCap":177346592},{"date":"2025-12-05","current":-7.082858,"twenty":-6.676544,"median":-5.869501,"eighty":-5.172026,"marketCap":170838460},{"date":"2025-12-12","current":-7.150314,"twenty":-6.706669,"median":-5.884194,"eighty":-5.183365,"marketCap":172465493},{"date":"2025-12-19","current":-6.764853,"twenty":-6.718803,"median":-5.896423,"eighty":-5.185781,"marketCap":163168162},{"date":"2025-12-26","current":-6.321572,"twenty":-6.721745,"median":-5.917556,"eighty":-5.189762,"marketCap":152476231},{"date":"2026-01-02","current":-5.897564,"twenty":-6.709975,"median":-5.917556,"eighty":-5.218313,"marketCap":142249167},{"date":"2026-01-09","current":-6.051748,"twenty":-6.706828,"median":-5.918043,"eighty":-5.231645,"marketCap":145968099},{"date":"2026-01-16","current":-5.12664,"twenty":-6.706347,"median":-5.916837,"eighty":-5.218313,"marketCap":123654504},{"date":"2026-01-23","current":-5.251915,"twenty":-6.701519,"median":-5.896423,"eighty":-5.230096,"marketCap":126676137},{"date":"2026-01-30","current":-4.567721,"twenty":-6.691045,"median":-5.884194,"eighty":-5.187481,"marketCap":110173374},{"date":"2026-02-06","current":-4.162986,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"marketCap":100411176},{"date":"2026-02-13","current":-4.085894,"twenty":-6.675886,"median":-5.86386,"eighty":-5.121593,"marketCap":98551710},{"date":"2026-02-20","current":-4.085894,"twenty":-6.6744,"median":-5.836285,"eighty":-5.109147,"marketCap":98551710},{"date":"2026-02-27","current":-3.806434,"twenty":-6.670885,"median":-5.810835,"eighty":-5.051947,"marketCap":91811145},{"date":"2026-03-06","current":-3.083693,"twenty":-6.66337,"median":-5.801368,"eighty":-5.014488,"marketCap":74378649},{"date":"2026-03-13","current":-2.457318,"twenty":-6.638594,"median":-5.7914,"eighty":-4.984609,"marketCap":59270486},{"date":"2026-03-20","current":-2.409136,"twenty":-6.610668,"median":-5.770478,"eighty":-4.925104,"marketCap":58108320},{"date":"2026-03-27","current":-2.421357,"twenty":-6.609918,"median":-5.754096,"eighty":-4.858871,"marketCap":53821570},{"date":"2026-04-02","current":-2.656026,"twenty":-6.605591,"median":-5.74824,"eighty":-4.848283,"marketCap":59037758},{"date":"2026-04-10","current":-2.016167,"twenty":-6.591355,"median":-5.726634,"eighty":-4.839764,"marketCap":44815069},{"date":"2026-04-17","current":-2.293524,"twenty":-6.585305,"median":-5.718473,"eighty":-4.830404,"marketCap":50980105},{"date":"2026-04-24","current":-2.698891,"twenty":-6.578607,"median":-5.699843,"eighty":-4.807832,"marketCap":59990542},{"date":"2026-05-01","current":-3.13626,"twenty":-6.553112,"median":-5.691423,"eighty":-4.789745,"marketCap":69712330},{"date":"2026-05-08","current":-3.562962,"twenty":-6.537578,"median":-5.687496,"eighty":-4.757961,"marketCap":79197001},{"date":"2026-05-15","current":-3.221727,"twenty":-6.536778,"median":-5.667354,"eighty":-4.71569,"marketCap":69384970},{"date":"2026-05-22","current":-2.688476,"twenty":-6.532441,"median":-5.647014,"eighty":-4.678926,"marketCap":57900561},{"date":"2026-05-29","current":-2.310756,"twenty":-6.527901,"median":-5.644452,"eighty":-4.628468,"marketCap":49765772},{"date":"2026-06-05","current":-2.155224,"twenty":-6.519006,"median":-5.637377,"eighty":-4.558084,"marketCap":46416152},{"date":"2026-06-12","current":-2.210771,"twenty":-6.519006,"median":-5.632466,"eighty":-4.465658,"marketCap":47612445},{"date":"2026-06-18","current":-2.277428,"twenty":-6.511576,"median":-5.624712,"eighty":-4.24967,"marketCap":49047996},{"date":"2026-06-26","current":-2.177443,"twenty":-6.50229,"median":-5.608839,"eighty":-4.114631,"marketCap":46894669},{"date":"2026-07-02","current":-1.599754,"twenty":-6.493669,"median":-5.581175,"eighty":-4.09553,"marketCap":34453226},{"date":"2026-07-10","current":-1.366457,"twenty":-6.488137,"median":-5.560665,"eighty":-4.043493,"marketCap":29428797},{"date":"2026-07-17","current":-1.844161,"twenty":-6.487388,"median":-5.541012,"eighty":-3.870035,"marketCap":39716914},{"date":"2026-07-24","current":-1.399785,"twenty":-6.484054,"median":-5.540019,"eighty":-3.587625,"marketCap":30146573},{"date":"2026-07-31","current":-1.2998,"twenty":-6.481308,"median":-5.528162,"eighty":-3.243011,"marketCap":27993246},{"date":"2026-08-07","current":-1.366457,"twenty":-6.480034,"median":-5.512491,"eighty":-3.170397,"marketCap":29428797},{"date":"2026-08-14","current":-1.083278,"twenty":-6.478922,"median":-5.507858,"eighty":-3.110658,"marketCap":23330098},{"date":"2026-08-21","current":-1.438793,"twenty":-6.475391,"median":-5.505609,"eighty":-3.053053,"marketCap":29428797},{"date":"2026-08-28","current":-1.984178,"twenty":-6.462834,"median":-5.488455,"eighty":-2.929275,"marketCap":40584001},{"date":"2026-09-04","current":-1.608476,"twenty":-6.447249,"median":-5.483192,"eighty":-2.791036,"marketCap":32899456},{"date":"2026-09-11","current":-1.350181,"twenty":-6.442378,"median":-5.478936,"eighty":-2.707024,"marketCap":27616332},{"date":"2026-09-18","current":-1.168434,"twenty":-6.440715,"median":-5.47715,"eighty":-2.66687,"marketCap":23898933},{"date":"2026-09-25","current":-0.727923,"twenty":-6.433572,"median":-5.471267,"eighty":-2.594882,"marketCap":14888805},{"date":"2026-09-29","current":-0.86435,"twenty":-6.429857,"median":-5.465779,"eighty":-2.465855,"marketCap":17679255}],"updateTime":1790773959332},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670838732","title":"There is a reason why your super is locked up until your 60s","url":"https://stock-news.laohu8.com/highlight/detail?id=2670838732","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670838732?lang=en_us&edition=fundamental","pubTime":"2026-09-28 00:00","pubTimestamp":1790524800,"startTime":"0","endTime":"0","summary":"This article was provided by a third-party and the opinions expressed here are the author’s. Morningstar values diversity of thought and publishes a broad range of viewpoints.Bill Kelty and Paul Keating were in furious agreement just four years ago on the 30th anniversary of the introduction of compulsory super in 1992. In their joint – and expansive – interview with the Australian Financial Review, they confirmed their belief that the ‘super wars’ between Labor and the Coalition were now ‘dead and buried’.Well so much for that idea!What’s the ideal policy for the contribution and access rules?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/retirement/there-is-reason-why-your-super-is-locked-up-until-your-60s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/retirement/there-is-reason-why-your-super-is-locked-up-until-your-60s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["SMC.AU","BK4144","BK4139","SMC","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669031167","title":"H.C. Wainwright Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669031167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669031167?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:55","pubTimestamp":1790013333,"startTime":"0","endTime":"0","summary":"In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Actuate Therapeutics, Inc., with a price target ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-actuate-therapeutics-inc-actu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-actuate-therapeutics-inc-actu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558985","title":"Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558985","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558985?lang=en_us&edition=fundamental","pubTime":"2026-09-10 05:00","pubTimestamp":1788987600,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on develo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3359097/0/en/actuate-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587909","title":"Actuate Reports Preclinical Synergy of Elraglusib with RAS Inhibitors in Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587909","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587909?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952224,"startTime":"0","endTime":"0","summary":"Actuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer modelsActuate Therapeutics disclosed new preclinical studies in pancreatic cancer combining elraglusib with R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL13PbDc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4588","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","BCDF","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587563","title":"Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with Ras Inhibitors Zoldonrasib and Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587563?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:05","pubTimestamp":1788951931,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660349012","title":"Push for major rental change for millions of AussiesThe move would reduce affordability and security problems for renters across the country.3 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2660349012","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660349012?lang=en_us&edition=fundamental","pubTime":"2026-08-19 00:00","pubTimestamp":1787068800,"startTime":"0","endTime":"0","summary":"Millions of Australian renters could be offered leases of at least two years under a union push to provide greater security amid the housing crisis. The Australian Council of Trade Unions (ACTU) will ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/sunrise/unions-unveil-plans-to-extend-standard-lease-agreements-and-increase-public-housing-amid-housing-crisis-c-22744622","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/sunrise/unions-unveil-plans-to-extend-standard-lease-agreements-and-increase-public-housing-amid-housing-crisis-c-22744622","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461847","title":"Actuate Therapeutics Price Target Maintained with a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461847?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:48","pubTimestamp":1787050080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469695","title":"Analyst Reiterates Buy on Actuate with Unchanged $15 Price Target Ahead of Key Elraglusib Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469695","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469695?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:15","pubTimestamp":1787048137,"startTime":"0","endTime":"0","summary":"Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Actuate Therapeutics, Inc. and keeping the price target at $15.00. S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-actuate-with-unchanged-15-price-target-ahead-of-key-elraglusib-trials-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-actuate-with-unchanged-15-price-target-ahead-of-key-elraglusib-trials-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659214971","title":"Actuate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659214971","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659214971?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:02","pubTimestamp":1786741341,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryActuate Therapeutics IncACTU.OQreported a quarterly adjusted loss of 20 cents per share for the quarter ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B1LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126004","title":"Actuate Therapeutics Q2 FY26 Net Loss Narrows to $4.87 Million; Operating Loss Improves to $4.91 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126004","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126004?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:11","pubTimestamp":1786738292,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Q2 FY26 net loss narrows to $4.87 million; operating loss improves to $4.91 millionActuate Therapeutics posted a Q2 net loss of $4.87 million, narrowing from $5.95 million a year ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL19W7md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900625","title":"Actuate Therapeutics Inc Expected to Post a Loss of 19 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900625","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900625?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:16","pubTimestamp":1786565765,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc <ACTU.OQ> expected to post a loss of19cents a share - Earnings PreviewActuate Therapeutics IncACTU.OQACTU.Ois expected to  show no change in quarterly revenue when it reports ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N44923J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655772138","title":"Actuate Therapeutics Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2655772138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655772138?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:29","pubTimestamp":1785414540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642287462","title":"Actuate Therapeutics’ Elraglusib Selected for Evaluation in Beacon2 Trial for High-Risk Pediatric Neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642287462?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:45","pubTimestamp":1781005533,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nFWN42H0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462256","title":"Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462256","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642462256?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:45","pubTimestamp":1781005526,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics’ elraglusib was selected for evaluation in BEACON2, a European Phase 1/2 platform trial in relapsed or refractory pediatric neuroblastoma.The study will test elraglusib with dinutuximab beta and chemotherapy, starting with a dose-confirmation stage focused on safety and dose selection.No BEACON2 results have been presented; data will be generated in the trial as it progresses.Prior early-stage clinical findings were previously reported, including a complete response in a heavily pretreated neuroblastoma patient in a separate Phase 1/2 study.The move expands elraglusib’s pediatric development path, supported by an FDA Rare Pediatric Disease designation for neuroblastoma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL2TySKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","ACTU","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462229","title":"Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462229","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642462229?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:45","pubTimestamp":1781005500,"startTime":"0","endTime":"0","summary":"- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham- Elraglusib wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308735/0/en/Actuate-Therapeutics-Elraglusib-Selected-for-Evaluation-in-BEACON2-Trial-for-High-Risk-Pediatric-Neuroblastoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721428933.USD","BK4181","LU0347712357.USD","IE00B5TLWC47.USD","LU2413666426.HKD","LU2413666699.HKD","BK4588","BK4218","PK","LU2211817866.USD","IE00BFXG0V08.USD","BK4585","BK4139","BK4533","LU1093756325.SGD","ACTU","BK4121","MTD","BK4548","IE00BYQQ9H92.USD","BK4567","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640463409","title":"Actuate Therapeutics posts ASCO presentation on elraglusib plus chemotherapy in metastatic pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640463409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640463409?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:41","pubTimestamp":1780407713,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics published a post-hoc efficacy and biomarker analysis from its phase 2 1801 Part 3B study in first-line metastatic pancreatic cancer.Landmark analysis in patients completing at least one cycle showed median overall survival of 12.5 months with elraglusib plus chemotherapy vs 8.5 months with chemotherapy alone.Subgroup results showed longer survival signals in patients with baseline albumin ≥3 g/dL or CA19-9 <8,000 U/mL on the elraglusib regimen.Exploratory biomarker work linked KRAS, TP53, CDKN2A, or SMAD4 alterations to worse survival only in the elraglusib arm.Outcomes appeared stronger in Europe than North America, with early mortality of 5.3% vs 15.4% in the elraglusib arm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL1zZLg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640220955","title":"Actuate says Phase 2 data show elraglusib plus chemo lifts survival in first-line metastatic pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640220955","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640220955?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:05","pubTimestamp":1780311945,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics reported Phase 2 elraglusib data in first-line metastatic pancreatic cancer at the 2026 ASCO Annual Meeting.Post-hoc analyses indicated longer survival in selected biomarker-defined patients receiving elraglusib with standard chemotherapy versus chemotherapy alone.A separate Phase 2 study suggested added clinical benefit when elraglusib was combined with FOLFIRINOX, with responses appearing deeper and more durable.Safety appeared manageable across regimens, supporting further development and potential positioning of elraglusib as a combination backbone therapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLbBm954:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","ACTU","BK4139","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955964","title":"Actuate Therapeutics Announces Asco Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955964?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:00","pubTimestamp":1780311602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUAW3TV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640407955","title":"Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640407955","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640407955?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:00","pubTimestamp":1780311600,"startTime":"0","endTime":"0","summary":"- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304175/0/en/Actuate-Therapeutics-Announces-ASCO-Poster-Presentations-Demonstrating-Compelling-Clinical-and-Biomarker-Data-for-Elraglusib-in-First-Line-Metastatic-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347120","title":"Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347120","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347120?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:24","pubTimestamp":1779488665,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) has issued an update. On May 21, 2026, Actuate Therapeutics, Inc. held its virtual Annual Meeting of Stockho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-stockholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-stockholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}]}}